JAK1 and peeling skin syndrome: The biological effects of ruxolitinib, a JAK1 and JAK2 inhibitor, on mesenchymal stromal cells (MSCs), isolated from salivary glands of both pSS patients and controls, have been recently evaluated in vitro.